Skip to main content
Erschienen in: Reactions Weekly 1/2015

01.04.2015 | Case report

Rhenium-188-etidronic acid

Thrombocytopenia and anaemia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Sabet A, et al. May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET?: A pilot report on 188Re-HEDP treatment in progressive bone metastases after 177Lu-octreotate. American Journal of Nuclear Medicine and Molecular Imaging 4: 80-88, No. 1, Jan 2014 - GermanyPubMedCentral Sabet A, et al. May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET?: A pilot report on 188Re-HEDP treatment in progressive bone metastases after 177Lu-octreotate. American Journal of Nuclear Medicine and Molecular Imaging 4: 80-88, No. 1, Jan 2014 - GermanyPubMedCentral
Metadaten
Titel
Rhenium-188-etidronic acid
Thrombocytopenia and anaemia: case report
Publikationsdatum
01.04.2015
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2015
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-015-0047-6

Weitere Artikel der Ausgabe 1/2015

Reactions Weekly 1/2015 Zur Ausgabe

Case report

Temozolomide

Case report

Metformin

Case report

Risperidone

Case report

Various drugs

Case report

Alitretinoin